136 related articles for article (PubMed ID: 36333130)
1. The frequency of change in five-point scale score with a Bayesian penalised likelihood PET reconstruction algorithm on interim FDG PET-CT and its potential implications for therapy decisions in Hodgkin's lymphoma.
Subesinghe M; Ilyas H; Dunn JT; Mir N; Duran A; Mikhaeel NG; Barrington SF
Clin Radiol; 2023 Feb; 78(2):e89-e98. PubMed ID: 36333130
[TBL] [Abstract][Full Text] [Related]
2. Factors affecting intrapatient liver and mediastinal blood pool ¹⁸F-FDG standardized uptake value changes during ABVD chemotherapy in Hodgkin's lymphoma.
Chiaravalloti A; Danieli R; Abbatiello P; Di Pietro B; Travascio L; Cantonetti M; Guazzaroni M; Orlacchio A; Simonetti G; Schillaci O
Eur J Nucl Med Mol Imaging; 2014 Jun; 41(6):1123-32. PubMed ID: 24562647
[TBL] [Abstract][Full Text] [Related]
3. Interim FDG-PET/CT for therapy monitoring and prognostication in Hodgkin's Lymphoma.
Al-Ibraheem A; Anwer F; Juweid ME; Shagera QA; Khalaf AN; Obeidat S; Mansour A; Ma'koseh M; Halahleh K; Jaradat I; Almasri N; Mansour A
Sci Rep; 2022 Oct; 12(1):17702. PubMed ID: 36271128
[TBL] [Abstract][Full Text] [Related]
4. The value of Bayesian penalized likelihood reconstruction for improving lesion conspicuity of malignant lung tumors on
Kurita Y; Ichikawa Y; Nakanishi T; Tomita Y; Hasegawa D; Murashima S; Hirano T; Sakuma H
Ann Nucl Med; 2020 Apr; 34(4):272-279. PubMed ID: 32060780
[TBL] [Abstract][Full Text] [Related]
5. Whole-body diffusion-weighted MR and FDG-PET/CT in Hodgkin Lymphoma: Predictive role before treatment and early assessment after two courses of ABVD.
Albano D; Patti C; Matranga D; Lagalla R; Midiri M; Galia M
Eur J Radiol; 2018 Jun; 103():90-98. PubMed ID: 29803392
[TBL] [Abstract][Full Text] [Related]
6. Does a novel penalized likelihood reconstruction of 18F-FDG PET-CT improve signal-to-background in colorectal liver metastases?
Parvizi N; Franklin JM; McGowan DR; Teoh EJ; Bradley KM; Gleeson FV
Eur J Radiol; 2015 Oct; 84(10):1873-8. PubMed ID: 26163992
[TBL] [Abstract][Full Text] [Related]
7. Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection.
Okosun J; Warbey V; Shaw K; Montoto S; Fields P; Marcus R; Virchis A; McNamara C; Bower M; Cwynarski K
AIDS; 2012 Apr; 26(7):861-5. PubMed ID: 22333746
[TBL] [Abstract][Full Text] [Related]
8. The impact of systemic chemotherapy on testicular FDG activity in young men with Hodgkin's lymphoma.
Burger IA; Vargas HA; Goldman DA; Gonen M; Kumar A; Zelenetz AD; Schöder H; Hricak H
Eur J Nucl Med Mol Imaging; 2013 May; 40(5):701-7. PubMed ID: 23389428
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy.
Sher DJ; Mauch PM; Van Den Abbeele A; LaCasce AS; Czerminski J; Ng AK
Ann Oncol; 2009 Nov; 20(11):1848-53. PubMed ID: 19541793
[TBL] [Abstract][Full Text] [Related]
10. Role of [18F]-FDG-PET/MDCT in evaluating early response in patients with Hodgkin's lymphoma.
Orlacchio A; Schillaci O; Gaspari E; Della Gatta F; Danieli R; Bolacchi F; Ragano Caracciolo C; Mancini A; Simonetti G
Radiol Med; 2012 Oct; 117(7):1250-63. PubMed ID: 22327919
[TBL] [Abstract][Full Text] [Related]
11. The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study.
Agostinelli C; Gallamini A; Stracqualursi L; Agati P; Tripodo C; Fuligni F; Sista MT; Fanti S; Biggi A; Vitolo U; Rigacci L; Merli F; Patti C; Romano A; Levis A; Trentin L; Stelitano C; Borra A; Piccaluga PP; Hamilton-Dutoit S; Kamper P; Zaucha JM; Małkowski B; Kulikowski W; Tajer J; Subocz E; Rybka J; Steidl C; Broccoli A; Argnani L; Gascoyne RD; d'Amore F; Zinzani PL; Pileri SA
Lancet Haematol; 2016 Oct; 3(10):e467-e479. PubMed ID: 27692305
[TBL] [Abstract][Full Text] [Related]
12. 2-deoxy-2[F-18] fluoro-D-glucose positron emission tomography Deauville scale and core-needle biopsy to determine successful management after six doxorubicin, bleomycin, vinblastine and dacarbazine cycles in advanced-stage Hodgkin lymphoma.
Picardi M; Fonti R; Della Pepa R; Giordano C; Pugliese N; Nicolai E; Salvatore M; Mainolfi C; Venetucci P; Rascato MG; Cappuccio I; Mascolo M; Vigliar E; Troncone G; Del Vecchio S; Pane F
Eur J Cancer; 2020 Jun; 132():85-97. PubMed ID: 32334339
[TBL] [Abstract][Full Text] [Related]
13. Changes of [
Liu Y; Gao MJ; Zhou J; Du F; Chen L; Huang ZK; Hu JB; Lou C
BMC Med Imaging; 2021 Sep; 21(1):133. PubMed ID: 34530768
[TBL] [Abstract][Full Text] [Related]
14. The effect of a novel Bayesian penalised likelihood PET reconstruction algorithm on the assessment of malignancy risk in solitary pulmonary nodules according to the British Thoracic Society guidelines.
Murphy DJ; Royle L; Chalampalakis Z; Alves L; Martins N; Bassett P; Breen R; Nair A; Bille A; Chicklore S; Cook GJ; Subesinghe M
Eur J Radiol; 2019 Aug; 117():149-155. PubMed ID: 31307640
[TBL] [Abstract][Full Text] [Related]
15. Evaluation and Optimization of a New PET Reconstruction Algorithm, Bayesian Penalized Likelihood Reconstruction, for Lung Cancer Assessment According to Lesion Size.
Otani T; Hosono M; Kanagaki M; Onishi Y; Matsubara N; Kawabata K; Kimura H
AJR Am J Roentgenol; 2019 Aug; 213(2):W50-W56. PubMed ID: 30995096
[No Abstract] [Full Text] [Related]
16. Hodgkin lymphoma: a negative interim-PET cannot circumvent the need for end-of-treatment-PET evaluation.
Mesguich C; Cazeau AL; Bouabdallah K; Soubeyran P; Guyot M; Milpied N; Bordenave L; Hindié E
Br J Haematol; 2016 Nov; 175(4):652-660. PubMed ID: 27539369
[TBL] [Abstract][Full Text] [Related]
17. Can We Predict Bleomycin Toxicity with PET-CT?
Beyhan Sagmen S; Comert S; Turan Erkek E; Küçüköz Uzun A; Doğan C; Yılmaz G; Kıral N; Fidan A; Yılmaz Haksal Ç; Torun Parmaksız E
Acta Haematol; 2019; 142(3):171-175. PubMed ID: 31454795
[TBL] [Abstract][Full Text] [Related]
18. Post-ABVD/pre-radiotherapy (18)F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: a retrospective analysis on 165 patients.
Ciammella P; Filippi AR; Simontacchi G; Buglione M; Botto B; Mangoni M; Iotti C; Merli F; Marcheselli L; Bisi G; Ricardi U; Versari A
Br J Radiol; 2016; 89(1061):20150983. PubMed ID: 27022777
[TBL] [Abstract][Full Text] [Related]
19. The predictive role of interim PET after the first chemotherapy cycle and sequential evaluation of response to ABVD in Hodgkin's lymphoma patients-the Polish Lymphoma Research Group (PLRG) Observational Study.
Zaucha JM; Malkowski B; Chauvie S; Subocz E; Tajer J; Kulikowski W; Fijolek-Warszewska A; Biggi A; Fallanca F; Kobylecka M; Dziuk M; Woszczyk D; Rybka J; Kroll-Balcerzak R; Bergesio F; Romanowicz A; Chamier-Cieminska A; Kurczab P; Giza A; Lesniewski-Kmak K; Zaucha R; Swietlik D; Wróbel T; Knopinska-Posluszny W; Walewski J; Gallamini A
Ann Oncol; 2017 Dec; 28(12):3051-3057. PubMed ID: 28950332
[TBL] [Abstract][Full Text] [Related]
20. Impact of baseline and interim quantitative PET parameters on outcomes of classical Hodgkin Lymphoma.
Santos FM; Marin JFG; Lima MS; Silva-Junior WF; Alves LBO; Moreira FR; Velasques RD; Atanazio MJ; Maia ACA; Buchpiguel CA; Buccheri V; Rocha V
Ann Hematol; 2024 Jan; 103(1):175-183. PubMed ID: 37796339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]